Gastrointestinal oncology
SOTIO Biotech a.s. focuses on advanced gastric adenocarcinoma and adenocarcinoma of the gastroesophageal junction, with research centred on treatment options for gastrointestinal malignancies that remain difficult to manage in later-stage disease.
- Gastric adenocarcinoma
- Gastroesophageal junction adenocarcinoma
- Advanced solid tumours
Its clinical interest in this area is directed toward tumour control in upper gastrointestinal cancers and the evaluation of novel targeted oncology approaches.
Pancreatic cancer
The sponsor also investigates pancreatic adenocarcinoma, a major area of unmet need in oncology, with attention to disease settings where therapeutic options are limited and outcomes are poor.
- Pancreatic adenocarcinoma
- Solid tumour treatment
- Anti-cancer therapy
This research domain reflects an interest in therapies aimed at improving tumour response in aggressive pancreatic malignancy.
Antibody-drug conjugates
SOTIO Biotech a.s. is active in the development of antibody-drug conjugate therapy, with a focus on targeted delivery strategies for cancer treatment in difficult-to-treat solid tumours.
- Antibody-drug conjugate
- Targeted oncology
- Tumour-directed therapy
The therapeutic emphasis lies in leveraging targeted mechanisms to address tumour-specific biology in gastrointestinal cancers.
Combination oncology treatment
The sponsor’s clinical research includes evaluation of its investigational therapy both as monotherapy and in combination with standard-of-care treatment, reflecting interest in integrated treatment strategies for advanced cancer.
- Monotherapy
- Combination therapy
- Standard-of-care treatment
This area is relevant to assessing how targeted agents may be used alongside established oncology regimens in refractory disease.
